COMBINED THERAPY USING AN ANTIBODY AGAINST TYPE II CD20 AND THE BCL-2 SELECTIVE INHIBITOR

摘要

1. A method of treating cancer in a person in need thereof, which comprises administering to said person an effective amount of GA101 antibody or 2- (1H-pyrrolo [2,3-b] pyridin-5-yloxy) -4- (4 - ((2 - (4-chlorophenyl) -4,4-dimethylcyclohex-1-enyl) methyl) piperazin-1-yl) -N- (3-nitro-4 - ((tetrahydro-2H-pyran-4-yl) methylamino) phenylsulfonyl ) benzamide or a pharmaceutically acceptable salt thereof for one or more dosing periods, and then co-administering an effective amount of said GA 101 antibody and 2- (1H-pyrrolo [2,3-b] pyridin-5-yloxy) -4- (4 - (( 2- (4-chlorophenyl) -4,4-dimethylcyclohex-1-enyl) methyl) piperazin-1-yl) -N- (3-nitro-4 - ((tetrahydro-2H-pyran-4-yl) methylamino) phenylsulfonyl) benzamide or a pharmaceutically acceptable salt thereof for one or more dosing periods. 2. A method of treating cancer in a person in need thereof, which comprises administering to said person an effective amount of GA101 antibody or 2- (1H-pyrrolo [2,3-b] pyridin-5-yloxy) -4- (4 - ((2- ( 4-chlorophenyl) -4,4-dimethylcyclohex-1-enyl) methyl) piperazin-1-yl) -N- (3-nitro-4 - ((tetrahydro-2H-pyran-4-yl) methylamino) phenylsulfonyl) benzamide or a pharmaceutically acceptable salt thereof for 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days, and then co-administration of an effective amount of said GA101 antibody and 2- (1H-pyrrolo [2,3-b] pyridin-5-yloxy) -4- (4 - ((2- (4-chloropheni l) -4,4-dimethylcyclohex-1-enyl) methyl) piperazin-1-yl) -N- (3-nitro-4 - ((tetrahydro-2H-pyran-4-yl) methylamino) phenylsulfonyl) benzamide or its a pharmaceutically acceptable salt for one or more dosing periods. 3. The method of claim 1, which comprises administering an effective amount of said GA101 antibody once for each dosing period for 1, 2, 3, 4, 5, or 6 cycles, followed by co-administration of an effective amount